560 related articles for article (PubMed ID: 29174215)
1. Choosing Dipeptidyl Peptidase-4 Inhibitors, Sodium-glucose Cotransporter-2 Inhibitors, or Both, as Add-ons to Metformin: Patient Baseline Characteristics Are Crucial.
Goldenberg RM
Clin Ther; 2017 Dec; 39(12):2438-2447. PubMed ID: 29174215
[TBL] [Abstract][Full Text] [Related]
2. Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials.
Scheen AJ
Diabetes Metab; 2020 Jun; 46(3):186-196. PubMed ID: 32007623
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of DPP-4 inhibitors, GLP-1 analogues, and SGLT2 inhibitors as add-ons to metformin monotherapy in T2DM patients: a model-based meta-analysis.
Inoue H; Tamaki Y; Kashihara Y; Muraki S; Kakara M; Hirota T; Ieiri I
Br J Clin Pharmacol; 2019 Feb; 85(2):393-402. PubMed ID: 30394576
[TBL] [Abstract][Full Text] [Related]
4. Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA1c Levels.
D'Andrea E; Wexler DJ; Kim SC; Paik JM; Alt E; Patorno E
JAMA Intern Med; 2023 Mar; 183(3):242-254. PubMed ID: 36745425
[TBL] [Abstract][Full Text] [Related]
5. Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study.
Sütő G; Molnár GA; Rokszin G; Fábián I; Kiss Z; Szekanecz Z; Poór G; Jermendy G; Kempler P; Wittmann I
BMJ Open Diabetes Res Care; 2021 Jan; 9(1):. PubMed ID: 33472796
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Wang Z; Sun J; Han R; Fan D; Dong X; Luan Z; Xiang R; Zhao M; Yang J
Diabetes Obes Metab; 2018 Jan; 20(1):113-120. PubMed ID: 28656707
[TBL] [Abstract][Full Text] [Related]
7. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Lingvay I
Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
[TBL] [Abstract][Full Text] [Related]
8. Comparison of SGLT2 inhibitors with DPP-4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus.
Lyu YS; Oh S; Kim JH; Kim SY; Jeong MH
Cardiovasc Diabetol; 2023 Jul; 22(1):185. PubMed ID: 37481509
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like-peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes in diabetes in relation to achieved glycemic control. A Danish nationwide study.
Zareini B; Sørensen KK; Pedersen-Bjergaard U; Loldrup Fosbøl E; Køber L; Torp-Pedersen C
J Diabetes; 2024 Jun; 16(6):e13560. PubMed ID: 38751369
[TBL] [Abstract][Full Text] [Related]
10. Sodium Glucose Cotransporter-2 Inhibitors as an Add-on Therapy to Metformin Plus Dipeptidyl Peptidase-4 Inhibitor in Patients with Type 2 Diabetes.
Bae J; Kim YE; Lee M; Lee YH; Lee BW; Cha BS; Kang ES
Yonsei Med J; 2022 Jun; 63(6):539-544. PubMed ID: 35619577
[TBL] [Abstract][Full Text] [Related]
11. Two years with GIOIA 'Effects of gliflozins and gliptins on markers of cardiovascular damage in type 2 diabetes': A prospective, multicentre, quasi-experimental study on sodium-glucose cotransporter 2 and dipeptidyl peptidase-4 inhibitors in diabetes clinical practice.
Longo M; Caruso P; Scappaticcio L; Maiorino MI; Bellastella G; Capuano A; Esposito K; Giugliano D
Diabetes Obes Metab; 2024 Apr; 26(4):1492-1501. PubMed ID: 38234208
[TBL] [Abstract][Full Text] [Related]
12. Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors.
Lee JY; Cho Y; Lee M; Kim YJ; Lee YH; Lee BW; Cha BS; Kang ES
Diabetes Metab J; 2019 Apr; 43(2):158-173. PubMed ID: 30688052
[TBL] [Abstract][Full Text] [Related]
13. Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome.
Bouzas C; Pastor R; Garcia S; Monserrat-Mesquida M; Martínez-González MÁ; Salas-Salvadó J; Corella D; Goday A; Martínez JA; Alonso-Gómez ÁM; Fernández-Barceló O; Vioque J; Romaguera D; Lopez-Miranda J; Estruch R; Tinahones FJ; Lapetra J; Serra-Majem L; Riquelme-Gallego B; Martín-Sánchez V; Pintó X; Delgado-Rodriguez M; Matía P; Vidal J; Cardenas-Salas JJ; Daimiel L; Ros E; Toledo E; Manzanares JM; Gonzalez-Monge I; Muñoz MÁ; Martinez-Urbistondo D; Tojal-Sierra L; Muñoz-Bravo C; Miralles-Gisbert S; Martin M; García-Ríos A; Castro-Barquero S; Fernández-García JC; Santos-Lozano JM; Basterra-Gortari FJ; Gutiérrez-Carrasquilla L; Guillem-Saiz P; Satorres A; Abete I; Sorto-Sanchez C; Díez-Espino J; Babio N; Fitó M; Tur JA
Biomed Pharmacother; 2023 May; 161():114561. PubMed ID: 36934556
[TBL] [Abstract][Full Text] [Related]
14. Health care utilization and costs associated with switching from DPP-4i to GLP-1RA or SGLT2i: an observational cohort study.
Newman TV; Munshi KD; Neilson LM; Good CB; Swart ECS; Huang Y; Henderson R; Parekh N
J Manag Care Spec Pharm; 2021 Apr; 27(4):435-443. PubMed ID: 33769857
[No Abstract] [Full Text] [Related]
15. Treatment patterns and satisfaction in patients with type 2 diabetes newly initiating oral monotherapy with antidiabetic drugs in Japan: results from the prospective Real-world Observational Study on Patient Outcomes in Diabetes (RESPOND).
Tajima A; Tobe K; Eiki JI; Origasa H; Watada H; Shimomura I; Tokita S; Kadowaki T
BMJ Open Diabetes Res Care; 2022 Dec; 10(6):. PubMed ID: 36585033
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019.
McCoy RG; Van Houten HK; Deng Y; Mandic PK; Ross JS; Montori VM; Shah ND
JAMA Netw Open; 2021 Feb; 4(2):e2035792. PubMed ID: 33523188
[TBL] [Abstract][Full Text] [Related]
17. Third-Line Antidiabetic Therapy Intensification Patterns and Glycaemic Control in Patients with Type 2 Diabetes in the USA: A Real-World Study.
Koye DN; Montvida O; Paul SK
Drugs; 2020 Apr; 80(5):477-487. PubMed ID: 32141024
[TBL] [Abstract][Full Text] [Related]
18. Metabolic effectiveness of gliflozins and gliptins in the routine clinical practice of patients with type 2 diabetes: preliminary results from GIOIA, a prospective multicentre study.
Esposito K; Longo M; Maiorino MI; Petrizzo M; Gicchino M; Bellastella G; Giugliano D
Diabetes Res Clin Pract; 2019 Sep; 155():107787. PubMed ID: 31326454
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of a sodium-glucose co-transporter-2 inhibitor versus placebo as an add-on therapy for people with type 2 diabetes inadequately treated with metformin and a dipeptidyl peptidase-4 inhibitor: a systematic review and meta-analysis of randomised controlled trials.
De Buitléir C; O' Connor E; Satti MM; Shaw J; Liew A
Diabet Med; 2021 Feb; 38(2):e14409. PubMed ID: 32979231
[TBL] [Abstract][Full Text] [Related]
20. Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis.
Mishriky BM; Tanenberg RJ; Sewell KA; Cummings DM
Diabetes Metab; 2018 Mar; 44(2):112-120. PubMed ID: 29477373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]